Novartis says novel antimalarial succeeded in late-stage trial
Source: SeekingAlpha
2025-11-13 09:14:25 ET
More on Novartis
- Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies Transcript
- Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies - Slideshow
- Novartis AG (NVS) Q3 2025 Earnings Call Transcript
- Novartis launches new manufacturing facility in California
- Key deals this week: Qorvo, Chewy, Sotherly Hotels, Novartis, CSG Systems, and more
Read the full article on Seeking Alpha
For further details see:
Novartis says novel antimalarial succeeded in late-stage trial
Novartis AG
NASDAQ: NVS
NVS Trading
1.0% G/L:
$148.41 Last:
2,532,809 Volume:
$147.65 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
